Intravenous Immunoglobulin (IVIG) therapy is the use of a mixture of antibodies (immunoglobulins) to treat health conditions including primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain-Barr? syndrome, and in certain other infections. Depending on the formulation it can be injected into muscle, a vein, or under the skin.

Increase in geriatric population, prevalence of immunodeficiency disorders and bleeding disorders have led to an increase in deamnd for novel intravenous immunoglobulin therapies. This has led to increase in the adoption rate of these therapies. Hence these factors have helped the market growth. However, stringent regulatory approval processes and regulations, and the high cost of therapy have been restraining the growth of the market.

Key Market Trends

Primary Immunodeficiency Diseases Treatment is Expected to Register a High CAGR

As per a report by Christine McCusker et al., published in Allergy, Asthma & Clinical Immunology Journal, 2018, Primary immunodeficiency diseases are more frequent than previously believed, with an estimated prevalence of 1 in 1200 live births. IgA deficiency is the most common PID, occurring in approximately 1 in 300 to 1 in 500 persons.

Intravenous immunoglobulin (IVIG) therapy has been used in primary immunodeficiency diseases (PI), other immune deficiency disorders. There are several specific medical therapies available for people with PI with antibody deficiency that account for more than half of the primary immunodeficiencies. These illnesses, such as Common Variable Immune Deficiency (CVID), X-Linked Agammaglobulinemia (XLA) and other disorders, are characterized by a lack of and/or impaired antibody function.

Hence, with availability of IVIG therapies for treating the high prevalent primary immunodeficiency diseases, the market is expected to grow in the future.

North America is Expected to Dominate the Intravenous Immunoglobulin Market

The North American countries like the United States (US) and Canada have a developed and well-structured health care system. These systems also encourage research and development. These policies encourage global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players.

Furthermore, these countries have a large portion of population that is insured. This enables this population to get medicines and therapies at subsidized rates. Hence, as increasing demand is met by the presence of global players in the region, the market is further expected to increase.

Competitive Landscape

Majority of the intravenous immunoglobulin therapies are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness. This has also helped the market grow.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support